J. Vincent, D. Backer, and D. , Circulatory shock, N Engl J Med, vol.369, issue.18, pp.1726-1760, 2013.

M. H. Weil and H. Shubin, Proposed reclassification of shock states with special reference to distributive defects, Adv Exp Med Biol, vol.23, issue.0, pp.13-23, 1971.

L. W. Busse, N. Barker, and C. Petersen, Vasoplegic syndrome following cardiothoracic surgery-review of pathophysiology and update of treatment options, Crit Care, p.4

B. Levy, C. Fritz, E. Tahon, A. Jacquot, T. Auchet et al., Vasoplegia treatments: the past, the present, and the future, Crit Care. 27 févr, vol.22, issue.1, p.52, 2018.

J. C. Jentzer, S. Vallabhajosyula, A. K. Khanna, L. S. Chawla, L. W. Busse et al.,

, Management of Refractory Vasodilatory Shock, CHEST. 1 août, vol.154, issue.2, pp.416-442, 2018.

A. Rhodes, L. E. Evans, W. Alhazzani, M. M. Levy, M. Antonelli et al., Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock, Intensive Care Med. mars, vol.43, issue.3, pp.304-77, 2016.

M. Singer, C. S. Deutschman, C. W. Seymour, M. Shankar-hari, D. Annane et al.,

, Sepsis-3), The Third International Consensus Definitions for Sepsis and Septic Shock, vol.315, pp.801-811, 2016.

J. P. Ortoleva, A Systematic Approach to the Treatment of Vasoplegia Based on Recent Advances in Pharmacotherapy, J Cardiothorac Vasc Anesth, vol.33, issue.5, pp.1310-1314, 2019.

A. Tsiouris, L. Wilson, A. S. Haddadin, J. J. Yun, and A. A. Mangi, Risk assessment and outcomes of vasoplegia after cardiac surgery, Gen Thorac Cardiovasc Surg, vol.65, issue.10, pp.557-65, 2017.

S. Omar, A. Zedan, and K. Nugent, Cardiac Vasoplegia Syndrome: Pathophysiology, Risk Factors and Treatment, The American Journal of the Medical Sciences. 1 janv, vol.349, issue.1, pp.80-88, 2015.

H. Liu, L. Yu, L. Yang, and M. S. Green, Vasoplegic syndrome: An update on perioperative considerations, J Clin Anesth. août, vol.40, pp.63-71, 2017.

S. Shaefi, A. Mittel, J. Klick, A. Evans, N. S. Ivascu et al., Vasoplegia After Cardiovascular Procedures-Pathophysiology and Targeted Therapy, J Cardiothorac Vasc Anesth, vol.32, issue.2, pp.1013-1035, 2018.

A. D. Shapeton, F. Mahmood, and J. P. Ortoleva, Hydroxocobalamin for the Treatment of

, Vasoplegia: A Review of Current Literature and Considerations for Use, J Cardiothorac Vasc Anesth. avr, vol.33, issue.4, pp.894-901, 2019.

A. C. St-andré and A. Delrossi, Hemodynamic management of patients in the first 24 hours after cardiac surgery, Crit Care Med. sept, vol.33, issue.9, pp.2082-93, 2005.

H. Ait-oufella, S. Gibot, A. Guillon, J. Mira, G. Monneret et al., Endothélium et microcirculation au cours des états critiques. Actes du séminaire de recherche translationnelle de la Société de réanimation de langue française, Réanimation. 1 juill, vol.25, issue.4, pp.431-440, 2016.

J. J. Patel, C. Venegas-borsellino, R. Willoughby, and J. K. Freed, High-Dose Vitamin B12 in Vasodilatory Shock: A Narrative Review, Nutr Clin Pract. août, vol.34, issue.4, pp.514-534, 2019.

P. C. Ng, T. B. Hendry-hofer, A. E. Witeof, M. Brenner, S. B. Mahon et al., Hydrogen Sulfide Toxicity: Mechanism of Action, Clinical Presentation, and Countermeasure Development, J Med Toxicol, vol.15, issue.4, pp.287-94, 2019.

D. W. Landry and J. A. Oliver, The pathogenesis of vasodilatory shock, N Engl J Med. 23 août, vol.345, issue.8, pp.588-95, 2001.

U. Pohl, J. Holtz, R. Busse, and E. Bassenge, Crucial role of endothelium in the vasodilator response to increased flow in vivo, Hypertension. 1 janv, vol.8, issue.1, pp.37-44, 1986.

H. K. Surks, N. Mochizuki, Y. Kasai, S. P. Georgescu, K. M. Tang et al., Regulation of

, Myosin Phosphatase by a Specific Interaction with cGMP-Dependent Protein Kinase I?. Science, vol.286, pp.1583-1590, 1999.

F. Kerbaul, C. Guidon, P. J. Lejeune, M. Mollo, T. Mesana et al., Hyperprocalcitonemia is related to noninfectious postoperative severe systemic inflammatory response syndrome associated with cardiovascular dysfunction after coronary artery bypass graft surgery, Journal of Cardiothoracic and Vascular Anesthesia. 1 févr, vol.16, issue.1, pp.47-53, 2002.

A. Ujike, K. Otsuguro, R. Miyamoto, S. Yamaguchi, and S. Ito, Bidirectional effects of hydrogen sulfide via ATP-sensitive K+ channels and transient receptor potential A1 channels in RIN14B cells, European Journal of Pharmacology, vol.764, pp.463-70, 2015.

O. Mccook, P. Radermacher, C. Volani, P. Asfar, A. Ignatius et al., H2S during circulatory shock: Some unresolved questions, Nitric Oxide. 15 sept, vol.41, pp.48-61, 2014.

C. Hartmann, P. Radermacher, M. Wepler, and B. Nußbaum,

. Catecholamines and . Shock, , vol.48, pp.390-400, 2017.

D. T. Andreis and M. Singer, Catecholamines for inflammatory shock: a Jekyll-and-Hyde conundrum, Intensive Care Med. sept, vol.42, issue.9, pp.1387-97, 2016.

J. C. Jentzer, B. Wiley, C. Bennett, D. H. Murphree, M. T. Keegan et al.,

, Temporal Trends and Clinical Outcomes Associated with Vasopressor and Inotrope Use In The Cardiac Intensive Care Unit, Shock. 4 juin, 2019.

M. Singer and M. A. Matthay, Clinical review: Thinking outside the box--an iconoclastic view of current practice, Crit Care. 26 juill, vol.15, issue.4, p.225, 2011.

M. Argenziano, J. M. Chen, A. F. Choudhri, S. Cullinane, E. Garfein et al.,

, Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent, J Thorac Cardiovasc Surg. déc, vol.116, issue.6, pp.973-80, 1998.

D. Morales, M. J. Garrido, J. D. Madigan, D. N. Helman, J. Faber et al., A double-blind randomized trial: prophylactic vasopressin reduces hypotension after cardiopulmonary bypass, Ann Thorac Surg. mars, vol.75, issue.3, pp.926-956, 2003.

S. Mehta, J. Granton, A. C. Gordon, D. J. Cook, S. Lapinsky et al., Cardiac ischemia in patients with septic shock randomized to vasopressin or norepinephrine, Crit Care. 20 juin, vol.17, issue.3, p.117, 2013.

L. A. Hajjar, J. L. Vincent, F. R. Barbosa-gomes-galas, A. Rhodes, G. Landoni et al., Vasopressin versus Norepinephrine in Patients with Vasoplegic Shock after Cardiac Surgery: The VANCS Randomized Controlled Trial, Anesthesiology, vol.126, issue.1, pp.85-93, 2017.

A. Khanna, S. W. English, X. S. Wang, K. Ham, J. Tumlin et al., Angiotensin II for the Treatment of Vasodilatory Shock, N Engl J Med, vol.03, issue.5, pp.419-449, 2017.

T. Fujii, N. Luethi, P. J. Young, D. R. Frei, G. M. Eastwood et al., Effect of Vitamin C, Hydrocortisone, and Thiamine vs Hydrocortisone Alone on Time Alive and Free of Vasopressor Support Among Patients With Septic Shock: The VITAMINS Randomized Clinical Trial, JAMA, vol.4, issue.2020, pp.423-454

D. Annane, S. M. Pastores, B. Rochwerg, W. Arlt, R. A. Balk et al., Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part I): Society of Critical Care Medicine (SCCM) and

, European Society of Intensive Care Medicine, vol.45, issue.12, pp.2078-2088, 2017.

V. N. Arevalo and M. L. Bullerwell, Methylene Blue as an Adjunct to Treat Vasoplegia in Patients Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass: A Literature Review, AANA J. déc, vol.86, issue.6, pp.455-63, 2018.

M. M. Weiner, H. Lin, D. Danforth, S. Rao, L. Hosseinian et al., Methylene Blue is Associated With Poor Outcomes in Vasoplegic Shock, Journal of Cardiothoracic and Vascular Anesthesia. 1 déc, vol.27, issue.6, pp.1233-1241, 2013.

R. L. Levin, M. A. Degrange, G. F. Bruno, C. Mazo, D. J. Taborda et al.,

, Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery, The Annals of Thoracic Surgery. 1 févr, vol.77, issue.2, pp.496-505, 2004.

L. Pasin, M. Umbrello, T. Greco, M. Zambon, F. Pappalardo et al., Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. Centre for Reviews and Dissemination (UK), 2013.

D. Sur, Fiche Piratox n°1: « Cyanures et dérivés cyanés », p.12, 2010.

K. Anseeuw, N. Delvau, G. Burillo-putze, D. Iaco, F. Geldner et al.,

, Cyanide poisoning by fire smoke inhalation: a European expert consensus, Eur J Emerg Med. févr, vol.20, issue.1, pp.2-9, 2013.

F. Charles, L. J. Murray, C. Giordano, and B. D. Spiess, Vitamin B12 for the treatment of vasoplegia in cardiac surgery and liver transplantation: a narrative review of cases and potential 35 biochemical mechanisms, Can J Anaesth. déc, vol.66, issue.12, pp.1501-1514, 2019.

K. Gerth, T. Ehring, M. Braendle, and P. Schelling, Nitric oxide scavenging by hydroxocobalamin may account for its hemodynamic profile, Clin Toxicol (Phila), p.44, 2006.

W. Uhl, A. Nolting, G. Golor, K. L. Rost, and A. Kovar, Safety of hydroxocobalamin in healthy volunteers in a randomized, placebo-controlled study, Clin Toxicol (Phila), vol.44, pp.17-28, 2006.

M. T. Zundel, J. T. Feih, J. Rinka, B. T. Boettcher, J. K. Freed et al.,

, Hydroxocobalamin With or Without Methylene Blue May Improve Fluid Balance in Critically Ill Patients With Vasoplegic Syndrome After Cardiac Surgery: A Report of Two Cases, J Cardiothorac Vasc Anesth, vol.32, issue.1, pp.452-459, 2018.

J. T. Feih, J. Rinka, and M. T. Zundel, Methylene Blue Monotherapy Compared With Combination Therapy With Hydroxocobalamin for the Treatment of Refractory Vasoplegic Syndrome: ARetrospective Cohort Study, J Cardiothorac Vasc Anesth. mai, vol.33, issue.5, pp.1301-1308, 2019.

Y. Lin and T. Q. Vu, Use of High-Dose Hydroxocobalamin for Septic Shock: A Case Report

A. Pract, , vol.12, pp.332-337, 2019.

Y. Cai, A. Mack, B. L. Ladlie, and A. K. Martin, The use of intravenous hydroxocobalamin as a rescue in methylene blue-resistant vasoplegic syndrome in cardiac surgery, Ann Card Anaesth. déc, vol.20, issue.4, pp.462-466, 2017.

T. J. Cios, B. Havens, B. Soleimani, and S. M. Roberts, Hydroxocobalamin treatment of refractory vasoplegia in patients with mechanical circulatory support, J Heart Lung Transplant. avr, vol.38, issue.4, pp.467-476, 2019.

S. S. An, C. P. Henson, R. E. Freundlich, and M. D. Mcevoy, Case report of high-dose hydroxocobalamin in the treatment of vasoplegic syndrome during liver transplantation, Am J Transplant, vol.18, issue.6, pp.1552-1557, 2018.

P. R. Shah, P. S. Reynolds, N. Pal, D. Tang, H. Mccarthy et al., Hydroxocobalamin for the treatment of cardiac surgery-associated vasoplegia: a case series, Can J Anaesth

A. Khwaja and . Kdigo, Clinical Practice Guidelines for Acute Kidney Injury, NEC, vol.120, issue.4, pp.179-84, 2012.

C. Paugam-burtz, E. Levesque, A. Louvet, D. Thabut, C. Bureau et al., LIVER FAILURE IN INTENSIVE CARE UNIT, p.53

, Acute Respiratory Distress Syndrome: The Berlin Definition, JAMA. 20 juin, vol.307, issue.23, pp.2526-2559, 2012.

C. Furnish, S. W. Mueller, T. H. Kiser, L. Dufficy, B. Sullivan et al.,

, Versus Methylene Blue for Vasoplegic Syndrome in Cardiothoracic Surgery: A Retrospective Cohort, J Cardiothorac Vasc Anesth, vol.23, issue.2020

V. S. Bebarta, N. Garrett, J. K. Maddry, A. Arana, S. Boudreau et al., A prospective, randomized trial of intravenous hydroxocobalamin versus noradrenaline or saline for treatment of lipopolysaccharide-induced hypotension in a swine model, Clinical and Experimental Pharmacology and Physiology, vol.46, issue.3, pp.216-241, 2019.

J. N. Tawil, D. Khatib, J. J. Jakobsons, H. J. Woehlck, C. Crouch et al., Unexpected Complication of, British Journal of Anaesthesia. 1 avr, vol.118, issue.4, 2017.

, Hydroxocobalamin Administration for Refractory Vasoplegia in Orthotopic Liver Transplant: A Case Report, Semin Cardiothorac Vasc Anesth. déc, vol.23, issue.4, pp.409-421, 2019.

C. Martin, S. Medam, F. Antonini, J. Alingrin, M. Haddam et al., NOREPINEPHRINE: NOT TOO MUCH, TOO LONG. Shock, vol.44, pp.305-314, 2015.

E. Rivers, B. Nguyen, S. Havstad, J. Ressler, A. Muzzin et al., ANNEXES : Annexe 1 : classification de l'IRA selon les critères KDIGO : IRA : insuffisance rénale aigue ; KDIGO : Kidney Disease Improving Global Outcomes Annexe 2 : Définition de BERLIN FiO2 : fraction inspirée en oxygène, N Engl J Med, vol.345, pp.1368-77, 2001.

. P/f, rapport Pa02/FiO2 RESUME Introduction : Le choc vasoplégique (CV) est caractérisé par un effondrement des résistances vasculaires aboutissant à une chute de pression de perfusion des organes

, Au travers de cas cliniques, l'hydroxocobalamine (HCB) a été décrite comme ayant un effet vasopresseur. L'objectif de ce travail était d'évaluer l

. Matériel, Ont été inclus les patients ayant reçu de l'HCB pour un état de CV. L'objectif de l'étude était de déterminer le nombre de patients répondeurs à l'HCB. Un patient était répondeur s'il avait une augmentation de plus de 20% de la pression artérielle moyenne (PAM), par rapport à la valeur avant le traitement, pendant au moins 15 minutes dans l'heure suivant l'administration de l'HCB. Les objectifs secondaires étaient de décrire l'évolution hémodynamique après administration d'HCB, de comparer les patients répondeurs (R) et non répondeurs (NR), Nous avons conduit une étude rétrospective observationnelle monocentrique au CHU d'Amiens en réanimation CTVR

, Chez les patients R, pendant les 120 minutes suivant l'administration, nous avons observé une augmentation significative de la PAM (p<0,0001) associée à une diminution non significative des doses de noradrénaline (p=0,9), Résultats : 18 patients ont été inclus, 6 patients (33%) étaient R et 12 (66%) étaient NR

, Avant l'administration d'HCB, les caractéristiques hémodynamiques cliniques et les paramètres biologiques étaient non différents entre les deux groupes. La PAM était de 63mmHg

, dans la population générale, de 68 mmHg

, Il n'existait aucune différence significative sur les données biologiques avant l'administration d'HCB. Il existait une tendance significative pour l'hémoglobine qui était de 10.4g/dL, p=0,08) chez les R et pour la SvO2 qui était de 67 %

, Conclusion : 33% des patients étaient R à l'HCB. Il n'existait aucune différence entre les NR et les R concernant les paramètres cliniques et biologiques avant administration

, Mots-clés : Vasoplégie, hydroxocobalamine, hémodynamique, réanimation, choc ABSTRACT Introduction: Vasoplegic shock (SV) is characterized by a decrease in vascular resistance resulting in a drop in organ perfusion pressure leading to death. Throught case reports or case series, hydroxocobalamin (HCB) has been described as having a vasopressor effect. The objective of this study was to evaluate the hemodynamic effect of HCB in SV

M. Material, The objective of the study was to determine the rate of responders. A patient was a responder in case of an increase of more than 20% in mean arterial pressure (MAP), for at least 15 minutes within one hour of HCB administration. The secondary objectives were to describe the hemodynamic course after hydroxocobalamin administration, to compare responder (R) and non-responder (NR) patients, and to assess the outcome of patients who received hydroxocobalamin in this indication. Results: Of the 18 patients included, 6 patients (33%) were R and 12 (66%) were NR, We conducted an observational retrospective study at the University Hospital of Amiens. Patients who received HCB for SV were included

, Prior to HCB administration, the clinical hemodynamic characteristics and biological parameters were not different between the two groups. MAP was 63 mmHg [57-74] in the general population, vol.68

, Conclusion: 33% of patients were R to HCB. There was no difference between NR and R in clinical and biological parameters prior to administration. Keywords: vasoplegia, hydroxocobalamin, hemodynamics